Reliance Jio (Expected Q2 2026): Strong GMP, massive valuation, but regulatory & market-risk loom large..Tata Capital (Expected Q4 2025): Moderate GMP, ₹17,200 cr issue, sensitive to interest rates & NBFC rules..Lenskart Solutions (Expected Q1 2026): Slightly positive GMP, ₹2,150 cr raise; competition & marketing risk..Pharmeasy (Expected Q1 2026): Neutral-to-positive GMP; ₹6,250 cr valuation, but regulatory & margin pressures..SBI Mutual Fund (Expected early 2026): Moderate GMP; ₹8,000 cr IPO, exposed to market AUM risk & competition..Read More Stories